XBiotech completes dosing of subjects in PK study being conducted in connection with MAA
XBiotech announced all subjects have been dosed in its PK study evaluating MABp1 half-life in healthy volunteers. This Phase I study will provide further PK data and will enable additional characterization of the PK of MABp1 at a 7.5mg/kg IV dose. Safety and tolerability will also be assessed. February 22, 2017